Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/9/2017
SIETES contiene 92006 citas

 
 
 1 a 20 de 1400 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
2. Cita con resumen
Nair NP, Chalmers L, Bereznicki BJ, Curtain C, Peterson GM, Connolly M, Bereznicki LR. Adverse drug reaction-related hospitalizations in elderly Australians: a prospective cross-sectional study in two Tasmanian hospitals. Drug Saf 2017;40:597-606. [Ref.ID 101969]
3.Enlace a cita original Cita con resumen
Butler J, Anstrom KJ, Felker GM, Givertz MM, Kalogeropoulos AP, Konstam MA, Mann DL, Margulies KB, NcNulty SE, Mentz RJ, Redfield MM, Tang WHW, Whellan DJ, Shah M, Desvigne-Nickens P, Hernandez AF, Braunwald E, National Heart Lung and Blood Institute Heart Failure Clinical Research Network. Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial. JAMA Cardiology 2017:12 de julio. [Ref.ID 101968]
4. Cita con resumen
Pierson-Marchandise M, Gras V, Moragny J, Micallef J, Gaboriau L, Picard S, Choukroun G, Masmoudi K, Liabeuf S, the French National Network of Pharmacovigilance Centres. The drugs that mostly frequently induce acute kidney injury: a case-noncase study of a pharmacovigilance database. Br J Clin Pharmacol 2017;83:1341-9. [Ref.ID 101945]
5. Cita con resumen
Mackenzie IS, Morant SV, Wei L, Thompson AM, MacDonald TM. Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. Br J Clin Pharmacol 2017;83:653-63. [Ref.ID 101935]
6. Cita con resumen
Anónimo. FDA announces list of off-patent drugs with no competition. DIA Daily 2017:1. [Ref.ID 101658]
7. Cita con resumen
Poudel DR, Acharya P, Ghimire S, Dhital R, Bharati R. Burden of hospitalizations related to adverse drug events in the USA: a retrospective analysis from large inpatient database. Pharmacoepidemiol Drug Saf 2017;26:635-41. [Ref.ID 101626]
8. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
9. Cita con resumen
Chan WY, Clark AB, Wilson AM, Loke YK, on behalf of the TIPAC investigators. The effect of co-trimoxazole on serum potassium concentration: safety evaluation of a randomized controlled trial. Br J Clin Pharmacol 2017;83:agosto. [Ref.ID 101544]
10. Cita con resumen
Anónimo. Drugs for hypertension. The Medical Letter on Drug and Therapeutics Bulletin 2017;59:41-8. [Ref.ID 101527]
11. Cita con resumen
Nardone B, Majewski S, Kim AS, Kiguradze T, Martínez-Escala EM, Friedland R, Amin A, Laumann AE, Edwards BJ, Rademaker AW, Martini MC, West DP. Melanoma and non-melanoma skin cancer associated with angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers and thiazides: a matched cohort study. Drug Saf 2017;40:249-55. [Ref.ID 101451]
12. Cita con resumen
Chobanian AV. Hypertension in 2017- What is the right target?. JAMA 2017;317:579-80. [Ref.ID 101415]
13. Cita con resumen
Anónimo. Spironolactone - potion or poison?. Drug Ther Bull 2017;55:13. [Ref.ID 101402]
14.Tiene citas relacionadas Cita con resumen
Puttnam R, Davis BR, Pressel SL, Whelton PK, Cushman WC, Louis GT, Margolis KL, Oparil S, Williamson J, Ghosh A, Einhorn PT, Barzilay JI, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group.. Association of 3 different antihypertensive medications with hip and pelvic fracture risk in older adults: secondary analysis of a randomized clinical trial. JAMA Intern Med 2017;177:67-76. [Ref.ID 101344]
15.Enlace a cita original Cita con resumen
Roustit M, Genty C, Lepelley M, Blaise S, Fromy B, Cracowski J-L, Bosson J-L. Amiloride treatment and increased risk of pressure ulcers in hospitalized patients. Br J Clin Pharmacol 2016;82:1685-7. [Ref.ID 101027]
17. Cita con resumen
Munson JC, Bynum JPW, Bell J-E, Cantu R, McDonough C, Wang Q, Tosteson TD, Tosteson ANA. Patterns of prescription drug use before and after fragility fracture. JAMA Intern Med 2016:22 de agosto. [Ref.ID 100584]
18. Cita con resumen
Finch A, Kubler P. The management of gout. Australian Prescriber 2016;39:1 de agosto. [Ref.ID 100572]
19. Cita con resumen
Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957-67. [Ref.ID 100151]
20. Cita con resumen
Griebeler ML, Kearns AE, Ryu E, Thapa P, Hathcock MA, Melton LJ, Wermers RA. Thiazide-associated hypercalcemia: incidence and association with primary hyperparathyroidism over two decades. J Clin Endocrinol Metab 2016;101:1166-73. [Ref.ID 100079]
Seleccionar todas
 
 1 a 20 de 1400 siguiente >>